List of Studies ( Metabolite:PC O-18:0/2:0)
| Study_id | Analysis_id | Study_title | Source | Species | Disease | Institute | Analysis Type |
|---|---|---|---|---|---|---|---|
| ST004205 | AN006992 | Lipidomic/Metabolomic Characterization of GPR34 KO, WT, TREM2 KO, and GPR34/TREM2 dKO iPSC1-derived microglia | Glial cells | Human | Neurodegenerative disease | Denali Therapeutics | LC-MS |
| ST004163 | AN006908 | Targeted Lipid Profiling of HEK and iPSC derived iMG Cell Models with GBA1 Loss-of-Function | Cultured cells | Human | Metabolic disease | Denali Therapeutics | LC-MS |
| ST004163 | AN006908 | Targeted Lipid Profiling of HEK and iPSC derived iMG Cell Models with GBA1 Loss-of-Function | Cultured cells | Human | Parkinsons disease | Denali Therapeutics | LC-MS |
| ST004059 | AN006714 | Targeted Lipid and Metabolite Profiling in Brains of ATP13A2 Knockout Mice | Brain | Mouse | Neurodegenerative disease | Denali Therapeutics | LC-MS |
| ST004059 | AN006714 | Targeted Lipid and Metabolite Profiling in Brains of ATP13A2 Knockout Mice | Brain | Mouse | Parkinsons disease | Denali Therapeutics | LC-MS |
| ST003501 | AN005746 | TREM2 expression level is critical for microglial state, metabolic capacity and efficacy of TREM2 agonism | Microglia | Mouse | Alzheimers disease | Denali Therapeutics | LC-MS |
